Jürgen Bernhagen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jürgen Bernhagen has a total of 860 co-authors. Here are the top co-authors by number of shared publications:
- Diego Megías
Instituto de Salud Carlos III
24 shared publications - Fatima Al-Shahrour
Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain
24 shared publications - Jesús Avila
Centro de Biología Molecular Severo Ochoa, CSIC-UAM, 28049 Madrid, Spain
24 shared publications - José Antonio Enríquez
Cardiovascular Regeneration Program, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
24 shared publications - Manuel Valiente
Spanish National Cancer Research Centre Madrid Spain
24 shared publications Adolfo de la Lama Zaragoza
23 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (19) , 5732-5751
The role of macrophage migration inhibitory factor (MIF) in the pathogenesis and progression of cardiovascular disease
Cardiovascular disease (CVD) remains the leading global cause of death, driven by complex mechanisms, in which chronic inflammation plays a central role. Inflammatory pathways contribute to all stages of CVD, from endothelial dysfunction and plaque formation to erosion, rupture and myocardial injury. Among the mediators implicated, macrophage migration inhibitory factor (MIF) has emerged as a pivotal player. MIF is a unique cytokine with chemokine‐like activity that promotes leukocyte recruitment, amplifies inflammatory cascades and modulates vascular function. Elevated circulating and tissue MIF levels correlate with disease severity, plaque instability and adverse outcomes in coronary artery disease and acute coronary syndrome, positioning MIF as both a biomarker and a therapeutic target. Preclinical studies demonstrate that MIF blockade, via small‐molecule inhibitors, engineered peptides or monoclonal antibodies, attenuates vascular inflammation and stabilizes plaques. However, clinical development for cardiovascular indications remains limited, with current trials focused on oncology and neuroinflammation. This review synthesizes current knowledge on MIF and its homologue D‐dopachrome tautomerase (D‐DT) in CVD, explores diagnostic and therapeutic potential and highlights emerging concepts such as sex differences. Understanding this axis could inform the development of novel immunocardiovascular therapies and personalized treatment strategies.
- 17 July 2026
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (19) , 5732-5751
Open AccessThe role of macrophage migration inhibitory factor (MIF) in the pathogenesis and progression of cardiovascular disease
Cardiovascular disease (CVD) remains the leading global cause of death, driven by complex mechanisms, in which chronic inflammation plays a central role. Inflammatory pathways contribute to all stages of CVD, from endothelial dysfunction and plaque formation to erosion, rupture and myocardial injury. Among the mediators implicated, macrophage migration inhibitory factor (MIF) has emerged as a pivotal player. MIF is a unique cytokine with chemokine‐like activity that promotes leukocyte recruitment, amplifies inflammatory cascades and modulates vascular function. Elevated circulating and tissue MIF levels correlate with disease severity, plaque instability and adverse outcomes in coronary artery disease and acute coronary syndrome, positioning MIF as both a biomarker and a therapeutic target. Preclinical studies demonstrate that MIF blockade, via small‐molecule inhibitors, engineered peptides or monoclonal antibodies, attenuates vascular inflammation and stabilizes plaques. However, clinical development for cardiovascular indications remains limited, with current trials focused on oncology and neuroinflammation. This review synthesizes current knowledge on MIF and its homologue D‐dopachrome tautomerase (D‐DT) in CVD, explores diagnostic and therapeutic potential and highlights emerging concepts such as sex differences. Understanding this axis could inform the development of novel immunocardiovascular therapies and personalized treatment strategies.
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Survival analysis of the 37-gene signature derived from CD74+ microglia/macrophages across TCGA primary tumors cohorts
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Survival analysis of the 37-gene signature derived from CD74+ microglia/macrophages across TCGA primary tumors cohorts
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 13 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Ibudilast reduces PD-L1 expression in CD74+ from patient-derived organotypic cultures
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 13 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Ibudilast reduces PD-L1 expression in CD74+ from patient-derived organotypic cultures
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 14 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Patient-derived organotypic cultures (PDOC) treated with Ibudilast
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 14 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Patient-derived organotypic cultures (PDOC) treated with Ibudilast
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Ibudilast reduces brain metastasis in vivo without comprising the viability of cancer cells in vitro
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Ibudilast reduces brain metastasis in vivo without comprising the viability of cancer cells in vitro
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 11 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Ibudilast reverts the protumorigenic signature of CD74+ microglia/macrophages in vivo
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 11 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Ibudilast reverts the protumorigenic signature of CD74+ microglia/macrophages in vivo
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 9 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Gene set enrichment analysis of CD74+ microglia/macrophages
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 9 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
Gene set enrichment analysis of CD74+ microglia/macrophages
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 10 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
List of marker genes defining each CD45⁺ immune cell population identified by single-cell RNA-seq
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 10 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
List of marker genes defining each CD45⁺ immune cell population identified by single-cell RNA-seq
- Open Access
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
List of flow cytometry antibodies
- 2 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from MIF-Induced CD74+ Microglia and Macrophages Promote Progression of Brain Metastasis and Are Clinically Relevant across Central Nervous System Disorders
List of flow cytometry antibodies